3 455

Cited 0 times in

Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers.

 Seho Park  ;  Hyung Seok Park  ;  Ja Seung Koo  ;  Woo Ick Yang  ;  Seung Il Kim  ;  Byeong-Woo Park 
 BREAST CANCER RESEARCH AND TREATMENT, Vol.133(1) : 311-320, 2012 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Hormonal/therapeutic use* ; Aromatase Inhibitors/therapeutic use* ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism* ; Breast Neoplasms/mortality ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Female ; Gene Expression ; Humans ; Kaplan-Meier Estimate ; Maintenance Chemotherapy ; Middle Aged ; Multivariate Analysis ; Neoplasms, Hormone-Dependent/drug therapy ; Neoplasms, Hormone-Dependent/metabolism* ; Neoplasms, Hormone-Dependent/mortality ; Proportional Hazards Models ; Receptors, Androgen/genetics ; Receptors, Androgen/metabolism* ; Receptors, Estrogen/metabolism ; Tissue Array Analysis ; Young Adult
Androgen receptor ; Breast cancer ; Estrogen receptor ; Predictive factor ; Prognosis
The aim was to investigate the implications of androgen receptor (AR) expression levels on outcomes for estrogen receptor (ER)-positive tumors. Immunohistochemically AR levels were determined from tissue microarrays of 614 ER-positive patients who received adjuvant endocrine with or without chemotherapy between November 1999 and August 2005. Characteristics and survival were analyzed using a Chi-square test, Kaplan-Meier methods, and Cox's models. AR levels were categorized into 3 subgroups as follows: low, AR < 10%; intermediate, 10% ≤ AR < 50%; high, AR ≥ 50%. Low, intermediate, and high AR levels were observed in 29.0, 44.0, and 27.0% of patients, respectively. High AR was associated with smaller size, nodal uninvolvement, grade I/II tumor, higher progesterone receptor expression, and lower proliferation index. With a median follow-up of 70.9 months, the high AR subgroup showed better survival, and these associations were maintained in 119 patients who received endocrine therapy alone [hazard ratio (HR), 0.111; 95% CI, 0.013-0.961 for disease-free survival (DFS); HR, 0.135; 95% CI, 0.015-1.208 for overall survival (OS)]. No significant benefits from chemotherapy were demonstrated in the high AR subgroup; however, the benefit from chemotherapy was significant among 448 AR-intermediate or -low patients (HR, 2.679; 95% CI, 1.452-4.944 for DFS; HR, 3.371; 95% CI, 1.611-7.052 for OS). High AR is an independent prognostic factor and a significant predictor for better endocrine-responsiveness in ER-positive tumors. AR-low or -intermediate levels could give an additional indication for use of chemotherapy in ER-positive tumors.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Koo, Ja Seung(구자승) ORCID logo https://orcid.org/0000-0003-4546-4709
Kim, Seung Il(김승일)
Park, Byeong Woo(박병우) ORCID logo https://orcid.org/0000-0003-1353-2607
Park, Se Ho(박세호) ORCID logo https://orcid.org/0000-0001-8089-2755
Park, Hyung Seok(박형석) ORCID logo https://orcid.org/0000-0001-5322-6036
Yang, Woo Ick(양우익) ORCID logo https://orcid.org/0000-0002-6084-5019
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.